Mazor Robotics Ltd. (MZOR) Price Target Raised to $28.00 at Barclays PLC
Mazor Robotics Ltd. (NASDAQ:MZOR) had its price target upped by Barclays PLC from $24.00 to $28.00 in a research report issued to clients and investors on Tuesday. The firm presently has an “overweight” rating on the stock. Barclays PLC’s target price indicates a potential upside of 8.15% from the stock’s current price.
Several other brokerages also recently weighed in on MZOR. B. Riley started coverage on Mazor Robotics in a report on Thursday. They set a “neutral” rating and a $25.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Tuesday, August 2nd. Zacks Investment Research cut Mazor Robotics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 14th. Finally, Standpoint Research started coverage on Mazor Robotics in a research report on Friday, July 8th. They set a “buy” rating and a $30.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $26.25.
Shares of Mazor Robotics (NASDAQ:MZOR) traded down 3.01% during midday trading on Tuesday, hitting $25.11. The stock had a trading volume of 154,575 shares. The firm’s market cap is $544.21 million. The stock’s 50 day moving average price is $23.28 and its 200 day moving average price is $18.14. Mazor Robotics has a 12 month low of $8.31 and a 12 month high of $26.55.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/mazor-robotics-ltd-mzor-price-target-raised-to-28-00-at-barclays-plc.html
Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Mazor Robotics had a negative return on equity of 42.30% and a negative net margin of 60.75%. The firm earned $8.30 million during the quarter, compared to the consensus estimate of $8.51 million. During the same period last year, the company earned ($0.05) earnings per share. The company’s revenue was up 6.4% on a year-over-year basis. On average, equities analysts forecast that Mazor Robotics will post ($0.71) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in MZOR. Iguana Healthcare Management LLC boosted its position in shares of Mazor Robotics by 60.0% in the second quarter. Iguana Healthcare Management LLC now owns 200,000 shares of the company’s stock valued at $3,596,000 after buying an additional 75,000 shares during the last quarter. Menta Capital LLC boosted its position in shares of Mazor Robotics by 25.0% in the second quarter. Menta Capital LLC now owns 46,848 shares of the company’s stock valued at $842,000 after buying an additional 9,366 shares during the last quarter. EAM Investors LLC purchased a new position in shares of Mazor Robotics during the second quarter valued at about $2,348,000. Cookson Peirce & Co. Inc. purchased a new position in shares of Mazor Robotics during the second quarter valued at about $192,000. Finally, Candriam Luxembourg S.C.A. purchased a new position in shares of Mazor Robotics during the second quarter valued at about $1,079,000. 18.71% of the stock is currently owned by institutional investors and hedge funds.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.